Wall Street Zen Downgrades Aktis Oncology (NASDAQ:AKTS) to Sell

Aktis Oncology (NASDAQ:AKTS) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other equities analysts have also recently issued reports on AKTS. William Blair began coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating for the company. Raymond James Financial initiated coverage on shares of Aktis Oncology in a report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on shares of Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th. HC Wainwright increased their target price on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Finally, Weiss Ratings upgraded Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Aktis Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $34.60.

Aktis Oncology Stock Performance

Aktis Oncology stock opened at $23.89 on Friday. The business’s 50-day moving average is $23.87. The firm has a market capitalization of $1.28 billion and a price-to-earnings ratio of -62.87. Aktis Oncology has a 52 week low of $14.72 and a 52 week high of $34.19.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings results on Monday, May 11th. The technology company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). The business had revenue of $3.23 million during the quarter, compared to the consensus estimate of $2.23 million. On average, sell-side analysts anticipate that Aktis Oncology will post -1.64 earnings per share for the current fiscal year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.